Belatacept and Tregs: Friends or foes?

Immunotherapy

Volumn 4, Issue 4, 2012, Pages 351-354

  Pilat, Nina ^a   Wekerle, Thomas ^a  

^a UNIVERSITY OF VIENNA   (Austria)

Author keywords

belatacept; costimulation blockade; CTLA4Ig; organ transplantation; tolerance; Tregs

Indexed keywords

BELATACEPT; CALCINEURIN INHIBITOR; CD28 ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; TRANSCRIPTION FACTOR FOXP3;

ALLOIMMUNITY; BINDING SITE; CD4+ CD25+ T LYMPHOCYTE; DRUG EFFICACY; EFFECTOR CELL; GRAFT SURVIVAL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY TRANSPLANTATION; LIGAND BINDING; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW; T LYMPHOCYTE ACTIVATION; T LYMPHOCYTE SUBPOPULATION;

HUMANS; IMMUNOCONJUGATES; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; LYMPHOCYTE ACTIVATION; T-LYMPHOCYTES, REGULATORY;

EID: 84860187339     PISSN: 1750743X     EISSN: 17507448     Source Type: Journal    
DOI: 10.2217/imt.12.13     Document Type: Review

References (39)

1. Malek TR. The biology of interleukin-2. Annu. Rev. Immunol. 26, 453-479 (2008). (Pubitemid 351600382)
2. Bluestone JA, Liu W, Yabu JM et al. The effect of costimulatory and interleukin 2 receptor blockade on regulatory T cells in renal transplantation. Am. J. Transplant. 8(10), 2086-2096 (2008).
3. Vondran FW, Timrott K, Tross J et al. Impact of basiliximab on regulatory T-cells early after kidney transplantation: down-regulation of CD25 by receptor modulation. Transplant. Int. 23(5), 514-523 (2010).
4. + regulatory T cells in vitro. Blood 111(7), 3675-3683 (2008).
5. Broady R, Yu J, Levings MK. ATG-induced expression of FOXP3 in human CD4(+)T cells in vitro is associated with T-cell activation and not the induction of FOXP3(+) T regulatory cells. Blood 114(24), 5003-5006 (2009).
6. +CD25 bright + regulatory T cells can mediate donor nonreactivity in long-term immunosuppressed kidney allograft patients. Am. J. Transplant. 6(12), 2955-2964 (2006).
7. + regulatory T cells. Blood 105 (12), 4743-4748 (20 05). (Pubitemid 40807298)
8. Sauer S, Bruno L, Hertweck A et al. T cell receptor signaling controls Foxp3 expression via PI3K, AKT, and mTOR. Proc. Natl Acad. Sci. USA 105(22), 7797-7802 (2008). (Pubitemid 351872718)
9. Wekerle T, Grinyo JM. Belatacept: from rational design to clinical application. Transplant. Int. 25, 139-150 (2012).
10. Larsen CP, Pearson TC, Adams AB et al. Rational development of LEA29Y (belatacept), a high-affnity variant of CTLA4-Ig with potent immunosuppressive properties. Am. J. Transplant. 5(3), 443-453 (2005). (Pubitemid 40313335)
11. Vincenti F, Larsen C, Durrbach A et al. Costimulation blockade with belatacept in renal transplantation. N. Engl. J. Med. 353(8), 770-781 (2005). (Pubitemid 41215486)
12. Vincenti F, Charpentier B, Vanrenterghem Y et al. A Phase 3 study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study). Am. J. Transplant. 10(3), 535-546 (2010).
13. Durrbach A, Pestana JM, Pearson T et al. A Phase 3 study of belatacept versus cyclosporine in kidney transplants from extended criteria donors (BENEFIT-EXT study). Am. J. Transplant. 10(3), 547-557 (2010).
14. Chavez H, Beaudreuil S, Abbed K et al. Absence of CD4CD25 regulatory T cell expansion in renal transplanted patients treated in vivo with belatacept mediated CD28-CD80/86 blockade. Transplant. Immunol. 17(4), 243-248 (2007). (Pubitemid 46687025)
15. Bestard O, Cassis L, Cruzado JM et al. Costimulatory blockade with mTOR inhibition abrogates effector T-cell responses allowing regulatory T-cell survival in renal transplantation. Transplant. Int. 24(5), 451-46 0 (2011).
16. Grimbert P, Audard V, Diet C et al. T-c e l l phenotype in protocol renal biopsy from transplant recipients treated with belatacept-mediated co-stimulatory blockade. Nephrol. Dial. Transplant. 26(3), 1087-1093 (2011).
17. + peripheral cells, and Tregs in graft biopsies from kidney transplant recipients under belatacept treatment. Transplant. Proc. 42(9), 3489-3496 (2010).
18. Muthukumar T, Dadhania D, Ding R et al. Messenger RNA for FOXP3 in the urine of renal-allograft recipients. N. Engl. J. Med. 353(22), 2342-2351 (2005). (Pubitemid 41713746)
19. Pilat N, Sayegh MH, Wekerle T. Costimulatory pathways in transplantation. Semin. Immunol. 23(4), 293-303 (2011).
20. Perez Vl, van Parijs L, Biuckians A, Zheng XX, Strom TB, Abbas AK. Induction of peripheral T cell tolerance in vivo requires CTLA-4 engagement. Immunity 6(4), 411-417 (1997). (Pubitemid 27208196)
21. Zheng XX, Markees TG, Hancock WW et al. CTLA4 signals are required to optimally induce allograft tolerance with combined donor-specific transfusion and anti-CD154 monoclonal antibody treatment. J. Immunol. 162(8), 4983-4990 (1999). (Pubitemid 29314906)
22. + regulatory T cell function. Science 322(5899), 271-275 (2008).
23. Walker LS, Sansom DM. The emerging role of CTLA4 as a cell-extrinsic regulator of T cell responses. Nat. Rev. Immunol. 11(12), 852-863 (2011).
24. Qureshi OS, Zheng Y, Nakamura K et al. Trans-endocytosis of CD80 and CD86: a molecular basis for the cell-extrinsic function of CTLA-4. Science 332(6029), 600-603 (2011).
25. Klein L, Jovanovic K. Regulatory T cell lineage commitment in the thymus. Semin. Immunol. 23(6), 401-409 (2011).
26. Hinterberger M, Wirnsberger G, Klein L. B7/CD28 in central tolerance: costimulation promotes maturation of regulatory T cell precursers and prevents their clonal deletion. Front. Immun. 2, 30 (2011).
27. + regulatory T cells. J. Immunol. 171(7), 3348-3352 (2003). (Pubitemid 37254533)
28. + immunoregulatory T cells that control autoimmune diabetes. Immunity 12(4), 431-440 (2000).
29. Bigenzahn S, Blaha P, Koporc Z et al. The role of non-deletional tolerance mechanisms in a murine model of mixed chimerism with costimulation blockade. Am. J. Transplant. 5(6), 1237-1247 (2005). (Pubitemid 40839411)
30. + regulatory T cells. Proc. Natl Acad. Sci. USA 105(27), 9331-9336 (2008).
31. Francisco LM, Salinas VH, Brown KE et al. PD-L1 regulates the development, maintenance, and function of induced regulatory T cells. J. Exp. Med. 206(13), 3015-3029 (2009).
32. Amarnath S, Mangus CW, Wang JC et al. The PDL1-PD1 axis converts human TH1 cells into regulatory T cells. Sci. Transl. Med. 3 (111), 111r a12 0 (2011).
33. Butte MJ, Keir ME, Phamduy TB, Sharpe AH, Freeman GJ. Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses. Immunity 27(1), 111-122 (2007). (Pubitemid 47089023)
34. Yang J, Riella LV, Chock S et al. The novel costimulatory programmed death ligand 1/B7.1 pathway is functional in inhibiting alloimmune responses in vivo. J. Immunol. 187(3), 1113-1119 (2011).
35. Lee RS, Rusche JR, Maloney ME, Sachs DH, Sayegh MH, Madsen JC. CTLA4Ig-induced linked regulation of allogeneic T cell responses. J. Immunol. 166(3), 1572-1582 (2001). (Pubitemid 32114637)
36. Wekerle T, Kurtz J, Bigenzahn S, Takeuchi Y, Sykes M. Mechanisms of transplant tolerance induction using costimulatory blockade. Curr. Opin Immunol. 14(5), 592-600 (2002).
37. Sucher R, Fischler K, Oberhuber R et al. IDO and regulatory T cell support are critical for cytotoxic T lymphocyte-associated ag-4 Ig-mediated long-term solid organ allograft survival. J. Immunol. 188(1), 37-46 (2011).
38. Pilat N, Baranyi U, Klaus C et al. Treg-therapy allows mixed chimerism and transplantation tolerance without cytoreductive conditioning. Am. J. Transplant. 10 (4), 751-762 (2010).
39. Pilat N, Klaus C, Gattringer M et al. Therapeutic effcacy of polyclonal Tregs does not require rapamycin in a low-dose irradiation bone marrow transplantation model. Transplantation 92(3), 280-288 (2011).